Is Spectrum Pharmaceuticals, Inc. (SPPI) Stock a Sell after Rajesh Shrotriya’s Insider Trading?; Kynikos Associates LP Decreased Its Lowes Cos (LOW) Position

Lowe's Companies, Inc. (NYSE:LOW) Logo

Kynikos Associates Lp decreased Lowes Cos Inc (LOW) stake by 75.98% reported in 2017Q4 SEC filing. Kynikos Associates Lp sold 58,811 shares as Lowes Cos Inc (LOW)’s stock declined 5.74%. The Kynikos Associates Lp holds 18,589 shares with $1.73M value, down from 77,400 last quarter. Lowes Cos Inc now has $70.70 billion valuation. The stock decreased 0.08% or $0.07 during the last trading session, reaching $85.62. About 2.03 million shares traded. Lowe's Companies, Inc. (NYSE:LOW) has risen 5.39% since May 16, 2017 and is uptrending. It has underperformed by 6.16% the S&P500.

More notable recent Lowe's Companies, Inc. (NYSE:LOW) news were published by: Globenewswire.com which released: “Investigation Relating to 401(k) Plan of Lowe’s Companies, Inc. (NYSE:LOW) Announced by Stull, Stull & Brody” on May 12, 2018, also Seekingalpha.com with their article: “Lowe’s Could Easily Double Its Dividend” published on May 13, 2018, Investorplace.com published: “Lowe’s Companies, Inc. Is Rallying — Grab Some Before the Earnings Spike” on May 14, 2018. More interesting news about Lowe's Companies, Inc. (NYSE:LOW) were released by: Bizjournals.com and their article: “Craftsman tools now stocked in Lowe’s stores” published on May 14, 2018 as well as Seekingalpha.com‘s news article titled: “Retirement Strategy: I Am Done Being Wrong About This Market” with publication date: May 16, 2018.

Investors sentiment decreased to 1.01 in Q4 2017. Its down 0.03, from 1.04 in 2017Q3. It dived, as 48 investors sold LOW shares while 437 reduced holdings. 138 funds opened positions while 351 raised stakes. 585.84 million shares or 0.67% less from 589.78 million shares in 2017Q3 were reported. Duff Phelps Invest Management Co stated it has 9,410 shares or 0.01% of all its holdings. Korea Investment has 1.02 million shares. Peoples Fincl Corporation, Pennsylvania-based fund reported 2,425 shares. Bnp Paribas Arbitrage holds 0.12% or 727,671 shares in its portfolio. Virtu Financial holds 19,322 shares. State Board Of Administration Of Florida Retirement Sys has 1.20 million shares for 0.3% of their portfolio. Dimensional Fund Advisors L P, a Texas-based fund reported 2.43M shares. Williams Jones And Ltd Co owns 128,950 shares. Planning Lc stated it has 20,288 shares or 0.66% of all its holdings. Lincoln Corporation owns 8,182 shares for 0.02% of their portfolio. Nuveen Asset Mgmt Lc has 0.14% invested in Lowe's Companies, Inc. (NYSE:LOW) for 236,727 shares. Wedge Capital L Lp Nc owns 194,049 shares. Gemmer Asset Ltd Liability Com has 0.03% invested in Lowe's Companies, Inc. (NYSE:LOW). Chevy Chase Hldgs has 726,345 shares. Folger Nolan Fleming Douglas Cap Mngmt Inc has invested 1.49% in Lowe's Companies, Inc. (NYSE:LOW).

Among 36 analysts covering Lowe’s Companies Inc. (NYSE:LOW), 23 have Buy rating, 0 Sell and 13 Hold. Therefore 64% are positive. Lowe’s Companies Inc. had 98 analyst reports since August 19, 2015 according to SRatingsIntel. As per Monday, September 25, the company rating was maintained by RBC Capital Markets. On Friday, March 2 the stock rating was maintained by BMO Capital Markets with “Market Perform”. Bernstein upgraded the shares of LOW in report on Monday, January 22 to “Outperform” rating. The rating was maintained by RBC Capital Markets with “Buy” on Tuesday, November 7. The stock has “Hold” rating by Topeka Capital Markets on Tuesday, May 24. Jefferies maintained Lowe's Companies, Inc. (NYSE:LOW) rating on Thursday, September 28. Jefferies has “Hold” rating and $75.0 target. SunTrust maintained the stock with “Hold” rating in Thursday, March 1 report. Stifel Nicolaus maintained it with “Buy” rating and $124.0 target in Wednesday, January 24 report. The firm has “Hold” rating given on Thursday, August 20 by Zacks. RBC Capital Markets maintained Lowe's Companies, Inc. (NYSE:LOW) on Wednesday, July 5 with “Buy” rating.

Analysts await Lowe's Companies, Inc. (NYSE:LOW) to report earnings on May, 23 before the open. They expect $1.24 EPS, up 20.39% or $0.21 from last year’s $1.03 per share. LOW’s profit will be $1.02B for 17.26 P/E if the $1.24 EPS becomes a reality. After $0.74 actual EPS reported by Lowe's Companies, Inc. for the previous quarter, Wall Street now forecasts 67.57% EPS growth.

Analysts await Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report earnings on August, 2. They expect $-0.23 earnings per share, up 11.54% or $0.03 from last year’s $-0.26 per share. After $-0.19 actual earnings per share reported by Spectrum Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.05% negative EPS growth.

Since March 21, 2018, it had 0 insider purchases, and 21 sales for $16.52 million activity. The insider SHROTRIYA RAJESH C MD sold $1.83 million. Riga Thomas J sold 1,948 shares worth $30,350. Turgeon Joseph W. sold $56,327 worth of stock or 3,100 shares. 2,640 shares valued at $47,868 were sold by GUSTAFSON KURT A on Thursday, March 22. 4,200 shares were sold by Krassner Stuart Mitchell, worth $78,278 on Wednesday, March 21.

Based on an average price-per-share of $17.6, Rajesh Shrotriya, the Spectrum Pharmaceuticals Inc’s director unloaded 84,014 shares of Spectrum Pharmaceuticals Inc worth approx. $1,481,777 U.S Dollars. He also sold 540,000 shares worth total $9,368,400 USD in the last 30 days. Rajesh Shrotriya presently holds 3.95 million shares or 3.84% of Spectrum Pharmaceuticals Inc’s market cap. The sale was made on May 14, 2018 and this act was unveiled in a document which was filed with the Washington-based Security and Exchange Commission. This document is on hand for review here.

Among 6 analysts covering Spectrum Pharma (NASDAQ:SPPI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharma has $3300 highest and $8.25 lowest target. $22.18’s average target is 24.12% above currents $17.87 stock price. Spectrum Pharma had 14 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was upgraded by Zacks on Thursday, August 27 to “Hold”. The firm has “Outperform” rating given on Friday, August 7 by RBC Capital Markets. The firm earned “Buy” rating on Thursday, August 24 by Jefferies. The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has “Outperform” rating given on Thursday, November 5 by RBC Capital Markets. The firm earned “Buy” rating on Monday, May 14 by FBR Capital. As per Tuesday, April 10, the company rating was maintained by FBR Capital. On Wednesday, June 7 the stock rating was maintained by Jefferies with “Buy”. The rating was reinitiated by H.C. Wainwright on Wednesday, August 16 with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Friday, May 4. The firm has “Buy” rating by Jefferies given on Monday, October 9.

More important recent Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news were published by: Seekingalpha.com which released: “Spectrum Pharmaceuticals’ (SPPI) CEO Joe Turgeon on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018, also Ocbj.com published article titled: “Midday Stock Roundup”, Nasdaq.com published: “Can These Top-Performing Biotech Stocks Keep Climbing?” on April 30, 2018. More interesting news about Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) was released by: Seekingalpha.com and their article: “Spectrum Pharmaceuticals: What To Expect From This Powerful Grower” with publication date: April 18, 2018.

Investors sentiment decreased to 1.63 in 2017 Q4. Its down 1.21, from 2.84 in 2017Q3. It turned negative, as 26 investors sold Spectrum Pharmaceuticals, Inc. shares while 28 reduced holdings. 27 funds opened positions while 61 raised stakes. 78.22 million shares or 9.25% more from 71.60 million shares in 2017Q3 were reported. Pnc Fincl Svcs Gru holds 0% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 3,177 shares. Hap Trading Ltd Limited Liability Company stated it has 0.03% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Kazazian Asset Management has 0.63% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 32,526 shares. Sei Company invested in 818 shares or 0% of the stock. Proshare Ltd Liability Company has invested 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Moreover, Panagora Asset Mgmt Inc has 0.04% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Ls Ltd Liability reported 0% stake. State Of Wisconsin Invest Board reported 58,000 shares. First Personal Financial Svcs stated it has 370 shares or 0% of all its holdings. D E Shaw And Incorporated reported 0.05% stake. Prudential Fincl has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). 32,490 were reported by Cubist Systematic Strategies Ltd. Kennedy Management Inc has invested 0.05% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Envestnet Asset Mngmt reported 3,690 shares or 0% of all its holdings. Ballentine Ltd Limited Liability Company holds 30,000 shares or 0.03% of its portfolio.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $1.84 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin??s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

The stock increased 1.94% or $0.34 during the last trading session, reaching $17.87. About 552,263 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has risen 143.80% since May 16, 2017 and is uptrending. It has outperformed by 132.25% the S&P500.

Lowe's Companies, Inc. (NYSE:LOW) Institutional Positions Chart